1. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children
- Author
-
Rénard, C., Barlogis, V., Mialou, V., Galambrun, C., Bernoux, D., Goutagny, Mp, Glasman, L., Loundou, Ad, Poitevin-Later, F., Dignat-George, Francoise, Dubois, V., Picard, C., Chabannon, C., Bertrand, Yves, Michel, G., Service de Pediatrie Debrousse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Laboratory of Biochemistry, Hopital Neurologique, Microbiologie Fondamentale et Pathogénicité (MFP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), UMR 6578 : Anthropologie Bio-Culturelle (UAABC), Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique (CNRS), Université Bordeaux Segalen - Bordeaux 2, and Microbiologie cellulaire et moléculaire et pathogénicité (MCMP)
- Subjects
Male ,MESH: Lymphocyte Count ,Adolescent ,Opportunistic Infections ,MESH: B-Lymphocytes/immunology ,T-Lymphocyte Subsets ,MESH: T-Lymphocyte Subsets/immunology ,MESH: Hematologic Diseases/therapy ,MESH: Lymphocyte Subsets/immunology ,Humans ,MESH: Female Hematologic Diseases/immunology ,Lymphocyte Count ,MESH: Male Opportunistic Infections/immunology ,MESH: Humans Infant ,Child ,Bone Marrow Transplantation ,MESH: Treatment Outcome ,MESH: Adolescent ,B-Lymphocytes ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Infant ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,MESH: Child Child, Preschool ,Hematologic Diseases ,Lymphocyte Subsets ,Killer Cells, Natural ,Treatment Outcome ,MESH: Killer Cells, Natural/immunology ,MESH: Cord Blood Stem Cell Transplantation/methods ,Child, Preschool ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,MESH: Bone Marrow Transplantation/methods ,Cord Blood Stem Cell Transplantation - Abstract
International audience; We report the post-transplant lymphocyte subset recovery of 226 children treated with Unrelated Cord Blood transplant (UCBT) (n = 112) or Unrelated Bone Marrow Transplant (UBMT) (n = 114) for malignant or non-malignant diseases. Absolute numbers of natural killer (NK), B and T cells were monitored by flow cytometry up to 5 years post-transplant. Immunological endpoints were: time to achieve a CD3(+) cell count > 0*5 and 1*5 × 10⁹/l, CD4(+) > 0*2 and 0*5 × 10⁹/l, CD8(+) > 0*25 ×10⁹/l, CD19(+) > 0*2 × 10⁹/l, NK > 0*1 × 10⁹/l. These endpoints were analysed through the use of cumulative incidence curves in the context of competing risks. CD8(+) T cell recovery was delayed after UCBT with a median time to reach CD8(+) T cells > 0*25 × 10⁹/l of 7*7 months whereas it was 2*8 months in UBMT (P < 0*001). B cell recovery was better in UCBT, with a median time to reach CD19(+) cells > 0*2 × 10⁹/l of 3*2 months in UCBT and 6*4 months in UBMT (P = 0*03). Median time for CD4(+) T cell and NK cell recovery was similar in UCBT and UBMT. CD4(+) T cells recovery was negatively correlated to age (better reconstitution in younger patients, P = 0*002). CD8(+) T cells recovery was shorter in recipients with a positive cytomegalovirus serology (P =0*001).
- Published
- 2011
- Full Text
- View/download PDF